{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:52:18Z","timestamp":1771681938601,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.xphs.2019.01.018","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T23:20:03Z","timestamp":1548372003000},"page":"2173-2179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice"],"prefix":"10.1016","volume":"108","author":[{"given":"Aya Hasan","family":"Al-Shammari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutsuna","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"9863","key":"10.1016\/j.xphs.2019.01.018_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.xphs.2019.01.018_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.xphs.2019.01.018_bib4","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.xphs.2019.01.018_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(12)70364-9","article-title":"Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial","volume":"13","author":"Eisen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.xphs.2019.01.018_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xphs.2019.01.018_bib7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","article-title":"Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis","volume":"31","author":"Belum","year":"2013","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/j.xphs.2019.01.018_bib8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/liv.13217","article-title":"Regorafenib induced severe toxic hepatitis: characterization and discussion","volume":"36","author":"Sacre","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.xphs.2019.01.018_bib9","series-title":"Clinical Pharmacology and Biopharmaceutics Review(s)","article-title":"Department of health and human services, food and drug administration","year":"2014"},{"key":"10.1016\/j.xphs.2019.01.018_bib10","series-title":"Stivarga Summary of Product Characteristics","year":"2014"},{"issue":"9","key":"10.1016\/j.xphs.2019.01.018_bib11","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A\u00a0phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.01.018_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-0625.2010.01237.x","article-title":"P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components","volume":"20","author":"Skazik","year":"2011","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2012.10.011","article-title":"ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate","volume":"165","author":"Hashimoto","year":"2013","journal-title":"J\u00a0Control Release"},{"issue":"7","key":"10.1016\/j.xphs.2019.01.018_bib14","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11095-014-1609-7","article-title":"Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1)","volume":"32","author":"Kort","year":"2015","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2019.01.018_bib15","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.xphs.2017.04.064","article-title":"Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites","volume":"106","author":"Fujita","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2019.01.018_bib16","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.153","article-title":"Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study","volume":"106","author":"Strumberg","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.117.076554","article-title":"Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib","volume":"46","author":"Ellawatty","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10637-013-9953-8","article-title":"Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics","volume":"32","author":"Sunakawa","year":"2014","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/j.xphs.2019.01.018_bib19","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cam4.883","article-title":"Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models","volume":"5","author":"Zopf","year":"2016","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.xphs.2019.01.018_bib20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.xphs.2019.01.018_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-017-3480-9","article-title":"Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects","volume":"81","author":"Gerisch","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2019.01.018_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1158\/0008-5472.CAN-15-0694","article-title":"Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death","volume":"76","author":"Zimmerman","year":"2016","journal-title":"Cancer Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919300346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919300346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:26:16Z","timestamp":1758360376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919300346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0022354919300346"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.01.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}